echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > Another batch of common medicine, the hospital will not be able to buy

    Another batch of common medicine, the hospital will not be able to buy

    • Last Update: 2020-11-18
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    "Pharmaceutical Network Industry Dynamics" Recently, Shanxi issued two notices, respectively, "on the announcement of the implementation of the drug production enterprises to withdraw the centralized procurement of the winning product platform registration qualification notice" "on the announcement of the implementation of the pharmaceutical production enterprises to apply for the cancellation of the direct hanging network product platform registration qualification notice."
    notice showed that 16 companies had offered a national commitment not to supply all 26 of their drugs, which also meant that the drugs would be withdrawn from the national public health market.
    According to combing statistics, 12 of the 26 drugs in 16 enterprises belong to the central tender for the winning basic drugs, including Shanxi Pude Pharmaceutical Co., Ltd. injection methotrexate, injection cyclophosphamide, Tianjin Jinyao Group Hubei Tian Pharmaceutical Co., Ltd. 4 varieties of cytophosphocholine sodium injection, carbonated lidocarin injection, glyphosate diamide injection, hydrochloric acid clintin injection.
    addition, there is no shortage of clinical large varieties in this withdrawal of drugs.
    , for example, Tianjin Jinyao Group Hubei Tian Pharmaceuticals announced the withdrawal of the drug sodium chloride injection, in 2018 China's public medical institutions terminal sales have reached 17.705 billion yuan.
    another drug, Klinmycin hydrochloride, with sales of 3.106 billion yuan in 2017 at the terminal of China's public medical institutions, according to data.
    fact, pharmaceutical enterprises take the initiative to apply for product cancellation, is a common phenomenon in the pharmaceutical industry in recent years.
    in some provinces, the withdrawal of the network and the commitment of the country's non-supply situation is constantly emerging. In January
    , Hainan Province Pharmaceutical Centralized Purchasing Center issued a notice, since April 2019 to accept a total of 250 applications for drug withdrawal, of which 171 are due to rising production costs, can not be normal supply, production line transformation, production line stoppage and other reasons.
    In May, Shanxi Province pharmaceutical centralized bidding procurement network hung two notices, including Chenxin Pharmaceuticals, Chengdu Teo Pharmaceutical Group, Stone Pharmaceutical Group, Ha Pharmaceutical Group, Shenwei Pharmaceuticals and other 25 enterprises applied to withdraw the direct hanging network product platform registration, involving 66 drug regulations, enterprises also made a national unified non-supply commitment.
    , such as sodium chloride injections, double yellow-linked particles, etc.
    in July, the Inner Mongolia Medical Insurance Bureau issued "on the summary publication of Texas German Pharmaceutical Co., Ltd. and other enterprises to apply for partial drug disqualification notice" said that Texas German Pharmaceuticals, Shanghai Modern Pharmaceuticals and other 20 pharmaceutical production enterprises (agent enterprises) due to rising raw materials, production line transformation and other reasons to Inner Mongolia to apply for the cancellation of 40 drugs hanging network qualification, and submitted a national unified non-supply commitment letter.
    face of many pharmaceutical companies have taken the initiative to apply for product revocation of the network, industry insiders said that enterprises to withdraw from the market is actually a last-of-last.
    In recent years, due to the rising raw materials and production costs, drug prices are too low, resulting in small profits of pharmaceutical companies, for strategic reasons, in order to protect prices, or to maintain a large amount of the market, can only choose to withdraw from the national recruitment market.
    fact, this also confirms from the side of the industry reshuffle intensified.
    the future for the remaining enterprises, in the face of low-cost drug waste standards, can only be given a reasonable profit, or do more and reduce costs.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.